BioCentury
ARTICLE | Company News

Xoma, Servier sales and marketing update

February 6, 2012 8:00 AM UTC

Xoma gained U.S. commercialization rights to Servier's Aceon perindopril erbumine, as well as options to develop and commercialize up to three products in the U.S. combining perindopril with other cardiovascular drugs in fixed-dose combinations. Xoma paid $1.5 million up front, and Servier is eligible for up to $8.5 million in development milestones and option fees, plus $15.1 million in sales milestones. Servier is also eligible for tiered royalties. ...